Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Paraganglioma × lanreotide × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 4 Carcinoid Tumor 3 Pheochromocytoma 1 Paraganglioma 1 Neoplasm Metastasis 1 Gastrointestinal Neoplasms 1 Carcinoma, Merkel Cell 1

Interventions

lutetium Lu 177 dotatate 5 Temozolomide 3 Specimen Handling 3 olaparib 2 belzutifan 2 anlotinib 2 Magnetic Resonance Spectroscopy 2 3-Iodobenzylguanidine 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 talazoparib 1 pazopanib 1 lanreotide 1 guadecitabine 1 gallium Ga 68 dotatate 1 copper dotatate CU-64 1 cabozantinib 1 atezolizumab 1 Sunitinib 1 Nivolumab 1 Lutetium-177 1 Lutetium 1 Ipilimumab 1 Fluorodeoxyglucose F18 1 Contrast Media 1 CTLA-4 Antigen 1 Biopsy 1 Axitinib 1 90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)- 1 3-fluorobenzylguanidine 1 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03946527 2026-03-02

LAMPARA

Columbia University

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡